OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Medical Economics is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
The economic impact of suboptimal treatment and treatment switch among patients with Crohn’s disease treated with a first-line biologic – A US retrospective claims database study	98
Number needed to treat (NNT) with pembrolizumab as an adjuvant therapy in resected patients with high-risk stage II (IIB and IIC) melanoma and its application to cost of preventing an event (COPE) in	82
Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States	56
Projected clinical and economic benefits of improved patent foramen ovale testing among cryptogenic stroke patients in the United States	50
Healthcare resource utilization patterns among patients with Parkinson’s disease psychosis and dementia: analysis of US Medicare beneficiaries treated with pimavanserin versus other-atypical antipsych	39
Health care resource utilization in the management of patients with Arginase 1 Deficiency in the US: a retrospective, observational, claims database study	38
Levalbuterol vs. albuterol for hospitalized patients with COPD in China: cost-utility and budget impact analysis	35
The economic burden of systemic lupus erythematosus in Taiwan	34
Economic evaluation of supplemental breast cancer screening modalities to mammography or digital breast tomosynthesis in women with heterogeneously and extremely dense breasts and average or intermedi	34
The economic impact of tobacco smoking and secondhand smoke exposure in Jordan: estimating the direct and indirect costs	33
Budget impact analysis of cenobamate, a novel adjunctive therapy for the treatment of drug resistant focal onset seizures, from the Belgian healthcare payer perspective	32
Economic burden of respiratory syncytial virus infection in adults: a systematic literature review	32
Micro-costing of genetic diagnostics in acute leukemia in Sweden: from standard-of-care to whole-genome sequencing	31
Reply to letter by Hadigal et al. regarding the cost-effectiveness of high dose quadrivalent vaccine in three European countries	27
Economic review of point-of-care EEG	27
Challenges in health economics research: insights from real-world examples	26
Initiating immunoglobulin replacement therapy helps reduce severe infections and shifts healthcare resource utilization to outpatient services among US patients with inborn errors of immunity	23
The impact of diagnosing provider type on longitudinal care for patients with newly diagnosed Huntington’s disease	23
Patient and physician preferences for treatment of hepatitis C virus infection in Japan: a discrete choice experiment	22
Cost-effectiveness analysis of carbetocin versus oxytocin for the prevention of postpartum hemorrhage following vaginal birth in the United Kingdom	22
Identification of cancer chemotherapy regimens and patient cohorts in administrative claims: challenges, opportunities, and a proposed algorithm	21
Effects of liposomal bupivacaine (LB) and provider experience with LB on service utilization, clinical outcomes, and Medicare expenditures among fee-for-service (FFS) beneficiaries	21
Cost-effectiveness of terlipressin for hepatorenal syndrome: the United States hospital perspective	21